Medicare tightens rules on diagnostic tests—but who pays the cost?

What it does

This bill requires Medicare to pay for electrodiagnostic services (nerve conduction studies and needle electromyography tests) only if they are performed at facilities that meet specific accreditation and quality standards, effective 3–4 years after enactment. The bill mandates that facilities have quality assurance programs, use approved equipment, employ trained personnel, and interpret results on-site in real time. The Secretary of Health and Human Services must designate accrediting organizations and establish an advisory committee to oversee standards and combat fraud.

Why we flagged it

The bill's core mechanism is a regulatory mandate requiring accreditation and quality standards for electrodiagnostic service providers under Medicare. While framed as fraud elimination, it functions primarily as a quality-assurance and facility-consolidation measure.

What the text implies

• The 3–4 year implementation window may allow incumbent accredited facilities to establish market dominance before smaller competitors can meet standards, potentially reducing provider competition.
• Accreditation requirements may disproportionately burden rural and safety-net providers with limited resources, reducing geographic access to these diagnostic services.
• The advisory committee's composition (dominated by healthcare practitioners, not patient advocates) may prioritize provider interests over patient affordability or access.
• Real-time on-site interpretation requirements may increase labor costs and operational complexity, potentially shifting costs to patients or reducing service availability in lower-margin markets.

Who it affects

Patients may benefit from higher-quality, fraud-resistant diagnostic services and reduced unnecessary testing, but the accreditation requirement could reduce access in rural or underserved areas and may increase costs for smaller providers, potentially limiting where patients can obtain these services.

Who stands to gain

• Accreditation organizations (newly designated gatekeepers)
• Large, well-capitalized diagnostic facilities able to meet accreditation standards
• Diagnostic equipment manufacturers (devices must meet specified technical standards)

Named in the bill

Medicare, HHS Secretary, Accreditation Council for Graduate Medical Education (ACGME), Royal College of Physicians and Surgeons of Canada, National Electrodiagnostic Services Advisory Committee, Electrodiagnostic service providers, Diagnostic equipment manufacturers

Where it stands

2 cosponsors: 2 Republicans.

• Apr 30, 2025 — Introduced · Congress.gov: “Introduced in House”
• Apr 30, 2025 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Dec 2025 to Dec 2025. Those filings disclosed $0 in lobbying spend. A filing names 1 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Pete Sessions, the sponsor, reported $561,450 in PAC receipts in the 2026 cycle.

• Aanem American Association of Neuromuscular and Electrodiagnostic Medicine — $0 on 1 filing

Lobbying Disclosure Act filings through Jan 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.